CCCC - Company ID 0001662579
The table below shows C4 Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $104.24M | $110.64M | $117.71M | $117.84M | $94.67M | $78.44M |
| SG&A |
C4 Therapeutics, Inc. reported annual revenue of $35.95M for fiscal year 2025. That is up 1.0% from $35.58M in fiscal 2024. Over the 5 fiscal years shown, annual revenue declined from $45.78M (FY 2021) to $35.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $36.20M |
| $42.12M |
| $42.08M |
| $42.79M |
| $33.25M |
| $15.20M |
| Operating income | -$115.22M | -$119.61M | -$139.03M | -$129.53M | -$82.13M | -$60.45M |
| Income tax | $121.00K | $131.00K | $1.28M | $0.00 | $0.00 | -$626.00K |
| Net income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M | -$66.33M |
| EPS (diluted) | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | - |